Precision Neuroscience, a developer of brain-computer interfaces, has successfully completed a Series C funding round, acquiring $102 million in investment. Spearheaded by General Equity Holdings, this round elevates the total fundraising figure to $155 million for the company. Joining this financial backing were B Capital, the Duquesne Family Office of investor Stanley F. Druckenmiller, and Steadview Capital, positioning Precision Neuroscience among the top-funded entities in the burgeoning BCI sector.
Earlier SEC documents suggested that the company had already acquired $93 million from the Series C funding. With this new capital injection, Precision Neuroscience aims to expand its workforce, underscore clinical research, and enhance forthcoming iterations of its AI-enhanced brain implant. Their unique Layer 7 thin-film BCI boasts 1,024 electrodes integrated in a flexible film that fits snugly against the brain, with a thickness only a fraction of a human hair.
The innovative device is designed to enable individuals with severe paralysis to navigate digital interfaces like computers and smartphones using their own mental commands.
“Our initial focus is on some of the most severe conditions—such as major spinal cord injuries, strokes, and ALS. Our ultimate aim is to produce a device that is both secure and scalable to address a wide spectrum of neurological issues,” commented Michael Mager, co-founder and CEO. “This funding milestone propels us closer to that ambition.”
Competitors like Neuralink, Synchron, and several others are also actively pursuing similar technological advancements. Over recent years, many such companies have been highlighted in MassDevice’s lists of leading BCI and neurotechnology firms: